Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchProton Pump InhibitorsPPIs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Death/intubation -34% Improvement Relative Risk Proton Pump Inhibitors  Freedberg et al.  Prophylaxis Is prophylaxis with proton pump inhibitors beneficial for COVID-19? PSM retrospective 1,620 patients in the USA Higher death/intubation with proton pump inhibitors (p=0.014) c19early.org Freedberg et al., Gastroenterology, May 2020 FavorsPPIs Favorscontrol 0 0.5 1 1.5 2+
PPIs for COVID-19
1st treatment shown to increase risk in September 2020, now with p = 0.00000012 from 39 studies.
5,100+ studies for 112 treatments. c19early.org
PSM retrospective 1,620 hospitalized patients in the USA, showing higher risk of combined death/intubation with PPI treatment.
Study covers proton pump inhibitors and famotidine.
risk of death/intubation, 34.0% higher, HR 1.34, p = 0.01, treatment 8 of 84 (9.5%), control 332 of 1,536 (21.6%), NNT 8.3, adjusted per study, propensity score matching, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Freedberg et al., 21 May 2020, retrospective, propensity score matching, USA, peer-reviewed, 15 authors.
This PaperPPIsAll
{ 'indexed': {'date-parts': [[2022, 1, 19]], 'date-time': '2022-01-19T16:47:56Z', 'timestamp': 1642610876500}, 'reference-count': 6, 'publisher': 'Elsevier BV', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2020, 9, 1]], 'date-time': '2020-09-01T00:00:00Z', 'timestamp': 1598918400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/100000002', 'name': 'National Institutes of Health', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'gastrojournal.org', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Gastroenterology'], 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1053/j.gastro.2020.05.053', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 22]], 'date-time': '2020-05-22T01:22:26Z', 'timestamp': 1590110546000}, 'page': '1129-1131.e3', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 130, 'title': [ 'Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 ' 'Patients: A Propensity Score Matched Retrospective Cohort Study'], 'prefix': '10.1053', 'volume': '159', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-2023-2899', 'authenticated-orcid': False, 'given': 'Daniel E.', 'family': 'Freedberg', 'sequence': 'first', 'affiliation': []}, {'given': 'Joseph', 'family': 'Conigliaro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Timothy C.', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kevin J.', 'family': 'Tracey', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michael V.', 'family': 'Callahan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Julian A.', 'family': 'Abrams', 'sequence': 'additional', 'affiliation': []}, {'given': 'Magdalena E.', 'family': 'Sobieszczyk', 'sequence': 'additional', 'affiliation': []}, {'given': 'David D.', 'family': 'Markowitz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aakriti', 'family': 'Gupta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Max R.', 'family': 'O’Donnell', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jianhua', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'David A.', 'family': 'Tuveson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhezhen', 'family': 'Jin', 'sequence': 'additional', 'affiliation': []}, {'given': 'William C.', 'family': 'Turner', 'sequence': 'additional', 'affiliation': []}, {'given': 'Donald W.', 'family': 'Landry', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1053/j.gastro.2020.05.053_bib1', 'series-title': 'American Society for Parenteral and Enteral Nutrition', 'author': 'Gottschlich', 'year': '2007'}, { 'key': '10.1053/j.gastro.2020.05.053_bib2', 'doi-asserted-by': 'crossref', 'first-page': 'PL365', 'DOI': '10.1016/S0024-3205(96)00553-X', 'volume': '59', 'author': 'Bourinbaiar', 'year': '1996', 'journal-title': 'Life Sci'}, { 'key': '10.1053/j.gastro.2020.05.053_bib3', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'volume': '10', 'author': 'Wu', 'year': '2020', 'journal-title': 'Acta Pharm Sin B'}, { 'key': '10.1053/j.gastro.2020.05.053_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1763', 'DOI': '10.1126/science.1085658', 'volume': '300', 'author': 'Anand', 'year': '2003', 'journal-title': 'Science'}, { 'key': '10.1053/j.gastro.2020.05.053_bib5', 'doi-asserted-by': 'crossref', 'first-page': '747', 'DOI': '10.1016/j.stem.2017.11.003', 'volume': '21', 'author': 'Chen', 'year': '2017', 'journal-title': 'Cell Stem Cell'}, { 'key': '10.1053/j.gastro.2020.05.053_bib6', 'doi-asserted-by': 'crossref', 'first-page': '6008', 'DOI': '10.1096/fj.202000502', 'volume': '34', 'author': 'Li', 'year': '2020', 'journal-title': 'FASEB J'}], 'container-title': ['Gastroenterology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0016508520347065?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0016508520347065?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 5, 19]], 'date-time': '2021-05-19T04:27:01Z', 'timestamp': 1621398421000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9]]}, 'references-count': 6, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2020, 9]]}}, 'alternative-id': ['S0016508520347065'], 'URL': 'http://dx.doi.org/10.1053/j.gastro.2020.05.053', 'relation': {}, 'ISSN': ['0016-5085'], 'issn-type': [{'value': '0016-5085', 'type': 'print'}], 'subject': ['Gastroenterology', 'Hepatology'], 'published': {'date-parts': [[2020, 9]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized ' 'COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Gastroenterology', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1053/j.gastro.2020.05.053', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2020 by the AGA Institute', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit